Editorial: Attention and Methylphenidate

Avi Avital¹, Iris Manor², David Coghill^{3

4}

Affiliations

¹ Department of Neuroscience, Rappaport Faculty of Medicine, Emek Medical Center, Technion - Israel Institute of Technology, Haifa, Israel.
² ADHD Clinic, Geha MHC and Clalit, Sackler School of Medicine, Tel Aviv, Israel.
³ Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.
⁴ Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.

Editorial

Avi Avital et al. Front Behav Neurosci. 2020.

. 2020 Apr 28:14:66.

doi: 10.3389/fnbeh.2020.00066. eCollection 2020.

Avi Avital¹, Iris Manor², David Coghill^{3

4}

¹ Department of Neuroscience, Rappaport Faculty of Medicine, Emek Medical Center, Technion - Israel Institute of Technology, Haifa, Israel.
² ADHD Clinic, Geha MHC and Clalit, Sackler School of Medicine, Tel Aviv, Israel.
³ Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.
⁴ Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.

No abstract available

Keywords: ADHD; adherence; anxiety; diagnosis; dose; dysregulation; methylphenidate; non-responder.

Comment on

1. Gaub M., Carlson C. L. (1997). Behavioral characteristics of DSM-IV ADHD subtypes in a school-based population. J. Abnormal Child Psychol. 25, 103–111. 10.1023/A:1025775311259 - DOI - PubMed
1. Heal D. J., Cheetham S. C., Smith S. L. (2009). The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 57, 608–618. 10.1016/j.neuropharm.2009.08.020 - DOI - PubMed
1. Linssen A. M. W., Sambeth A., Vuurman E. F. P. M., Riedel W. J. (2014). Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. Int. J. Neuropsychopharmacol. 17, 961–977. 10.1017/S1461145713001594 - DOI - PubMed
1. Mahone E. M., Denckla M. B. (2017). Initial opinions on the effects of Phenylbutazone (PBZ) and historical prospective. J. Int. Neuropsychol. Soc. 23, 916–929. 10.1017/S1355617717000807 - DOI - PMC - PubMed
1. O'Driscoll G. A., Dépatie L., Holahan A. L. V., Savion-Lemieux T., Barr R. G., Jolicoeur C., et al. . (2005). Executive functions and methylphenidate response in subtypes of attention-deficit/hyperactivity disorder. Biol. Psychiatry 57, 1452–1460. 10.1016/j.biopsych.2005.02.029 - DOI - PubMed